Literature DB >> 18955684

The HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis.

M Lou1, A Safdar, M Mehdiratta, S Kumar, G Schlaug, L Caplan, D Searls, M Selim.   

Abstract

OBJECTIVE: To develop a grading scale to predict the risk of intracerebral hemorrhage (ICH) and prognosis after treatment with IV tissue-plasminogen activator (t-PA) in patients with ischemic stroke.
METHODS: We constructed a five-point scale based on NIH Stroke Scale score, extent of hypodensity on CT scan, serum glucose at baseline, and history of diabetes to predict the risk of hemorrhage after thrombolysis (HAT score). We evaluated the predictive ability of this scale, using c-statistics, in two independent cohorts: the t-PA treated group in the National Institute of Neurological Disorders and Stroke study, and consecutive patients treated with IV t-PA at our institution.
RESULTS: The percentage of patients who developed any ICH after t-PA increased with higher scores in both cohorts. Collectively, the rate of any symptomatic ICH was 2% (0 point), 5% (1 point), 10% (2 points), 15% (3 points), and 44% (>3 points). The c-statistic was 0.72 (95% CI 0.65-0.79; p < 0.001) for all hemorrhages; 0.74 (0.63-0.84; p < 0.001) for symptomatic hemorrhages; and 0.79 (0.70-0.88; p < 0.001) for hemorrhages with final fatal outcome. Similar results were obtained when each cohort was analyzed separately. The score also reasonably predicted good (mRS < or = 2) (c-statistic 0.75; 0.69-0.80; p < 0.001) and catastrophic (mRS > or = 5) (0.78; 0.72-0.84; p < 0.001) functional outcomes on day 90 in the National Institute of Neurological Disorders and Stroke t-PA-treated patients.
CONCLUSIONS: The hemorrhage after thrombolysis (HAT) score is a practical, quick, and easy-to-perform scale that allows reasonable risk stratification of intracerebral hemorrhage after IV tissue-plasminogen activator (t-PA). However, the prognostic value of this scale and its use to predict the net benefit from t-PA needs to be refined and prospectively confirmed in a larger cohort of patients before it can be used in clinical decision-making.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18955684      PMCID: PMC2676961          DOI: 10.1212/01.wnl.0000330297.58334.dd

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

1.  Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).

Authors:  V Larrue; R von Kummer R; A Müller; E Bluhmki
Journal:  Stroke       Date:  2001-02       Impact factor: 7.914

2.  MRI features of intracerebral hemorrhage within 2 hours from symptom onset.

Authors:  I Linfante; R H Llinas; L R Caplan; S Warach
Journal:  Stroke       Date:  1999-11       Impact factor: 7.914

3.  Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.

Authors:  S C Patel; S R Levine; B C Tilley; J C Grotta; M Lu; M Frankel; E C Haley; T G Brott; J P Broderick; S Horowitz; P D Lyden; C A Lewandowski; J R Marler; K M Welch
Journal:  JAMA       Date:  2001-12-12       Impact factor: 56.272

4.  Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey.

Authors:  David Tanne; Scott E Kasner; Andrew M Demchuk; Nira Koren-Morag; Sandra Hanson; Martin Grond; Steven R Levine
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

5.  Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis.

Authors:  Chelsea S Kidwell; Jeffrey L Saver; Joaquin Carneado; James Sayre; Sidney Starkman; Gary Duckwiler; Y Pierre Gobin; Reza Jahan; Paul Vespa; J Pablo Villablanca; David S Liebeskind; Fernando Vinuela
Journal:  Stroke       Date:  2002-03       Impact factor: 7.914

6.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

7.  Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator.

Authors:  Marc Ribo; Joan Montaner; Carlos A Molina; Juan F Arenillas; Esteban Santamarina; Manuel Quintana; José Alvarez-Sabín
Journal:  Stroke       Date:  2004-07-08       Impact factor: 7.914

8.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

Authors:  Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

9.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

Authors:  W Hacke; M Kaste; C Fieschi; D Toni; E Lesaffre; R von Kummer; G Boysen; E Bluhmki; G Höxter; M H Mahagne
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

10.  Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume.

Authors:  Magdy Selim; John N Fink; Sandeep Kumar; Louis R Caplan; Clare Horkan; Yi Chen; Italo Linfante; Gottfried Schlaug
Journal:  Stroke       Date:  2002-08       Impact factor: 7.914

View more
  66 in total

1.  Computed Tomography Perfusion Derived Blood-Brain Barrier Permeability Does Not Yet Improve Prediction of Hemorrhagic Transformation.

Authors:  Alexander D Horsch; Edwin Bennink; Tom van Seeters; L Jaap Kappelle; Yolanda van der Graaf; Willem P T M Mali; Hugo W A M de Jong; Birgitta K Velthuis; Jan Willem Dankbaar
Journal:  Cerebrovasc Dis       Date:  2018-01-08       Impact factor: 2.762

Review 2.  Stroke Research in China over the Past Decade: Analysis of NSFC Funding.

Authors:  Lijun Zhu; Dongsheng He; Lijuan Han; Heqi Cao
Journal:  Transl Stroke Res       Date:  2015-06-05       Impact factor: 6.829

3.  TURN Score Predicts 90-day Outcome in Acute Ischemic Stroke Patients After IV Thrombolysis.

Authors:  David Asuzu; Karin Nyström; Joseph Schindler; Charles Wira; David Greer; Janet Halliday; Kevin N Sheth
Journal:  Neurocrit Care       Date:  2015-10       Impact factor: 3.210

4.  Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke).

Authors:  Andrew D Barreto; Gary A Ford; Loren Shen; Claudia Pedroza; Jon Tyson; Chunyan Cai; Mohammad H Rahbar; James C Grotta
Journal:  Stroke       Date:  2017-05-15       Impact factor: 7.914

5.  Challenges enrolling patients with acute ischemic stroke into cell therapy trials.

Authors:  Farhaan S Vahidy; Susan Alderman; Sean I Savitz
Journal:  Stem Cells Dev       Date:  2012-10-15       Impact factor: 3.272

Review 6.  Therapies for Hemorrhagic Transformation in Acute Ischemic Stroke.

Authors:  Joshua A Stone; Joshua Z Willey; Salah Keyrouz; James Butera; Ryan A McTaggart; Shawna Cutting; Brian Silver; Bradford Thompson; Karen L Furie; Shadi Yaghi
Journal:  Curr Treat Options Neurol       Date:  2017-01       Impact factor: 3.598

Review 7.  Considering hyperglycemia and thrombolysis in the Stroke Hyperglycemia Insulin Network Effort (SHINE) trial.

Authors:  Andrew M Southerland; Karen C Johnston
Journal:  Ann N Y Acad Sci       Date:  2012-09       Impact factor: 5.691

Review 8.  Hemorrhagic transformation after ischemic stroke in animals and humans.

Authors:  Glen C Jickling; DaZhi Liu; Boryana Stamova; Bradley P Ander; Xinhua Zhan; Aigang Lu; Frank R Sharp
Journal:  J Cereb Blood Flow Metab       Date:  2013-11-27       Impact factor: 6.200

9.  Clinical predictors and management of hemorrhagic transformation.

Authors:  Raphaella E Weiser; Kevin N Sheth
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

10.  Advanced imaging improves prediction of hemorrhage after stroke thrombolysis.

Authors:  Bruce C V Campbell; Søren Christensen; Mark W Parsons; Leonid Churilov; Patricia M Desmond; P Alan Barber; Kenneth S Butcher; Christopher R Levi; Deidre A De Silva; Maarten G Lansberg; Michael Mlynash; Jean-Marc Olivot; Matus Straka; Roland Bammer; Gregory W Albers; Geoffrey A Donnan; Stephen M Davis
Journal:  Ann Neurol       Date:  2013-02-26       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.